The catecholamine dopamine plays a major role in the regulation of cognitive, emotional and behavioral functions, and abnormalities in its regulation have been implicated in a number of psychiatric and neurological disorders. Dopamine acts through D2-like (D2, D3, D4) and D1-like (D1, D5) receptors, which are members of the seven transmembrane segment G protein-coupled receptor (GPCR) superfamily. The long-term goals of this project are: 1) to understand the structural bases of agonist and antagonist binding and specificity in dopamine receptors and related biogenic amine receptors and 2) to determine how agonist binding is transduced into G protein activation. Many drugs used to treat psychiatric disorders, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), and depression, target dopamine receptors, either directly or indirectly. We propose the following specific aims: 1. To determine the functional stoichiometry of the signaling unit of the dopamine D2 receptor (D2R), a representative Family A GPCR. We will determine whether two receptors signal through a single heterotrimeric G protein, the number of agonists required to activate a single signaling unit of D2R, and the role of agonist or antagonist binding to the second protomer in homomeric and heteromeric signaling units. 2. To determine the specificity of D2R heterodimerization in neurons in primary culture and in vivo in Drosophila melanogaster using biochemical, biophysical, and optical methods. 3. To differentiate the role of signaling of D2R homomers and heteromers using a novel resonance energy transfer based-biosensor for G protein activation. To complete our objectives we will combine experimental, structural, and computational approaches to receptor structure and function. In addition to work in heterologous cells, we will use mouse nucleus accumbens medium spiny neurons in primary culture and Drosophila melanogaster as a model system to dissect further the importance of homo- and heteromeric receptor signaling in vivo. Moreover, we will use our newly developed energy transfer based-biosensor to link biophysically the heteromeric receptor complex with G protein activation in real time. 7. PUBLICE

Public Health Relevance

Many drugs used to treat psychiatric disorders, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), and depression, target dopamine receptors, either directly or indirectly. That dopamine receptors may exist and function in homo- and heteromeric complexes with other GPCRs opens new pharmacological possibilities that will be best exploited if based on a clear understanding of the mechanistic basis of this signaling crosstalk.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH054137-16
Application #
8120954
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (02))
Program Officer
Brady, Linda S
Project Start
1995-09-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
16
Fiscal Year
2011
Total Cost
$500,578
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Yano, Hideaki; Provasi, Davide; Cai, Ning Sheng et al. (2017) Development of novel biosensors to study receptor-mediated activation of the G-protein ? subunits Gs and Golf. J Biol Chem 292:19989-19998
Zheng, Qinsi; Jockusch, Steffen; Zhou, Zhou et al. (2017) Electronic tuning of self-healing fluorophores for live-cell and single-molecule imaging. Chem Sci 8:755-762
Sykes, David A; Moore, Holly; Stott, Lisa et al. (2017) Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun 8:763
Abdallah, Chadi G; Hannestad, Jonas; Mason, Graeme F et al. (2017) Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biol Psychiatry Cogn Neurosci Neuroimaging 2:449-456
Clark, Lindsay D; Dikiy, Igor; Chapman, Karen et al. (2017) Ligand modulation of sidechain dynamics in a wild-type human GPCR. Elife 6:
Gregorio, G Glenn; Masureel, Matthieu; Hilger, Daniel et al. (2017) Single-molecule analysis of ligand efficacy in ?2AR-G-protein activation. Nature 547:68-73
Michino, Mayako; Boateng, Comfort A; Donthamsetti, Prashant et al. (2017) Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor. J Med Chem 60:580-593
Niswender, Colleen M; Jones, Carrie K; Lin, Xin et al. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chem Neurosci 7:1201-11
DeLorenzo, Christine; Gallezot, Jean-Dominique; Gardus, John et al. (2016) In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [(11)C]ABP688 and [(18)F]FPEB. J Cereb Blood Flow Metab :271678X16673646
Stolzenberg, Sebastian; Michino, Mayako; LeVine, Michael V et al. (2016) Computational approaches to detect allosteric pathways in transmembrane molecular machines. Biochim Biophys Acta 1858:1652-62

Showing the most recent 10 out of 87 publications